Outcomes of Newly Diagnosed Acute Myeloid Leukemia Patients Treated With Hypomethylating Agents With or Without Venetoclax: A Propensity Score-Adjusted Cohort Study

There is a deficiency of real-world data on the impact of combining venetoclax (VEN) with hypomethylating agents (HMAs) in newly diagnosed acute myeloid leukemia (AML) patients. We conducted a single-center, propensity-adjusted retrospective cohort study to compare composite complete remission (CCR)...

Descripción completa

Detalles Bibliográficos
Autores principales: Mustafa Ali, Moaath K., Corley, Elizabeth M., Alharthy, Hanan, Kline, Kathryn A. F., Law, Jennie Y., Lee, Seung Tae, Niyongere, Sandrine, Duong, Vu H., Emadi, Ashkan, Baer, Maria R.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008336/
https://www.ncbi.nlm.nih.gov/pubmed/35433414
http://dx.doi.org/10.3389/fonc.2022.858202

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9008336/
https://www.ncbi.nlm.nih.gov/pubmed/35433414
http://dx.doi.org/10.3389/fonc.2022.858202

Ejemplares similares